Search company, investor...

Predict your next investment

Venture Capital
techvp.co.uk

Investments

22

Portfolio Exits

1

About Technology Venture Partners (UK)

Technology Venture Partners (TVP) invests in high growth companies across a broad range of technology sectors including enterprise and infrastructure software, communications and networking, electronics, advanced materials, medical technology and healthcare IT.

Headquarters Location

The Innovation Centre, Bristol and Bath Science Park Dirac Crescent, Emersons Green

Bristol, England, BS16 7FR,

United Kingdom

0117 370 7740

Want to inform investors similar to Technology Venture Partners (UK) about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest Technology Venture Partners (UK) News

PE HUB » Atlas Genetics Gets Funded Backers include South West Ventures Fund and Finance South Wales Growth Fund.

Jan 14, 2015

February 13, 2008     0 Comments Atlas Genetics, a Bath-based developer of point-of-care molecular diagnostics for such indications as MRSA and meningitis, has raised Gbp2.1 million in VC funding. PRESS RELEASE South West Ventures Fund and Finance South West Growth Fund have led a Gbp2.1m further funding round in the Bath-based company, Atlas Genetics, which is developing a 'point of care' molecular diagnostic platform that gives clinicians results in less than 30 minutes from taking the patient sample. The company is currently working on tests for meningitis, Chlamydia, Group B Streptococcus and the hospital “super-bug” MRSA. The company, formed in 2005 as a spin-out from Bath University, has raised the additional funds to conduct a clinical evaluation for the detection of Group B Streptococcus in pregnant women, an infection which can lead to life-threatening sepsis and meningitis in neo-natal children. This latest round sees further funding being provided by existing investors, South West Ventures Fund, GEIF and private investors through the SWAIN business angel's network. New investors in the round are the Finance South West Growth Fund and Braveheart Ventures. Atlas Genetics is developing the point of care VeloxTM system, a portable device which delivers the benefits of molecular testing together with laboratory quality results, within 30 minutes. This allows doctors to test and treat a patient within a single visit or to have a specific diagnosis in an emergency situation. This equates to better outcomes for patients. In addition it allows clinicians to prescribe the most effective drug rather than use broad-based antibiotics which can encourage “super-bugs”. In the VeloxTM system a patient sample, such as blood or urine, is loaded directly into a disposable card which is then inserted into a reader instrument. An electronic tag developed by the company automatically indicates the presence of DNA from the pathogen responsible for the infection. This technology offers significant advantages over conventional methods and makes it feasible to produce a simple to use and portable device with the sensitivity and specificity of central laboratory equipment. Development of the disposable card is being undertaken with the world-leading micro-fluidic company Micronics Inc, based in Seattle. Dr John Clarkson, Chief Executive Officer of Atlas Genetics, said: “The initial funding secured from our investors has enabled us to produce the prototype disposable card, and this second round will take us through development to the point where the Group B Strep system can be evaluated with clinical samples.”   Nick Simmonds, Investment Manager at YFM Group, manager of the South West Ventures Fund, said: “This second round of funding will allow Atlas Genetics to develop a platform for many exciting applications. The market for point of care molecular diagnostics is expanding rapidly and is allowing earlier treatment of potentially serious infections. We are delighted to back Atlas Genetics and look forward to working closely with the company as it develops.”

Technology Venture Partners (UK) Investments

22 Investments

Technology Venture Partners (UK) has made 22 investments. Their latest investment was in Symetrica as part of their Unattributed VC - IV on June 6, 2019.

CBI Logo

Technology Venture Partners (UK) Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/18/2019

Unattributed VC - IV

Symetrica

$3.76M

Yes

1

4/17/2019

Unattributed VC - III

MedVet

$2.85M

Yes

1

6/19/2018

Series D

Micrima

$5.8M

No

3

1/23/2017

Series D

Subscribe to see more

$99M

Subscribe to see more

10

9/1/2016

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/18/2019

4/17/2019

6/19/2018

1/23/2017

9/1/2016

Round

Unattributed VC - IV

Unattributed VC - III

Series D

Series D

Series C

Company

Symetrica

MedVet

Micrima

Subscribe to see more

Subscribe to see more

Amount

$3.76M

$2.85M

$5.8M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

1

3

10

10

Technology Venture Partners (UK) Portfolio Exits

1 Portfolio Exit

Technology Venture Partners (UK) has 1 portfolio exit. Their latest portfolio exit was NanoSight on October 01, 2013.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/1/2013

Acquired

$99M

1

Date

10/1/2013

Exit

Acquired

Companies

Valuation

$99M

Acquirer

Sources

1

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.